$デルキャス・システムズ(DCTH.US)$Publication of Results from Pivotal FOCUS Study in Metastatic Uveal Melanoma Patients treated with HEPZATO KIT 1 MINUTE AGO, 9:00 AM EDT VIA PR NEWSWIRE Significantly Higher Overall Response Rate vs Meta-analysis of Historical Controls (36.3% vs. 5.5%) Other Efficacy Endpoints Include a 73.6% Disease Control Rate with a 7.7% Complete Response Rate
Trytosaveabitスレ主AGP:
Sry! Didn’t have time to read details! Good they have money without financing it! Bad if the shares are diluting? Good if the shares are locked up for 6 months or better? Or if shares are unregistered! Sry best I got I’m in several volatile trades
$デルキャス・システムズ(DCTH.US)$J-codes are reimbursement codes used by commercial insurance plans, Medicare, Medicare Advantage, and other government payers for Medicare Part B drugs like Jelmyto that are administered by a physician. Claims submission and payment are standardized with a J-code, facilitating and streamlining billing and reimbursement.
$デルキャス・システムズ(DCTH.US)$Moomoo 24/7· 1 min ago Delcath Systems Launches Commercial Treatment Utilizing HEPZATO KIT For Treatment Of Metastatic Uveal Melanoma
$デルキャス・システムズ(DCTH.US)$Officer MICHEL GERARD J purchased 34,000 shares of Common Stocks on Dec 8, 2023 at an average price of $2.94 for a total value of $99,960.
$デルキャス・システムズ(DCTH.US)$So the company is entitled to a 25 million milestone payment when the reach 10M in revenue in a quarter! And with this that i found in DD? They just may reach that in Q4/23-Q1/24? Good chance if this all goes as planned? ((( An interim futility analysis conducted in September resulted in the independent data monitoring committee recommending continuing the study without modification; and •Partnered with seven clinical treatment sites to ...
デルキャス・システムズに関するコメント
1 MINUTE AGO, 9:00 AM EDT
VIA PR NEWSWIRE
Significantly Higher Overall Response Rate vs Meta-analysis of Historical Controls (36.3% vs. 5.5%)
Other Efficacy Endpoints Include a 73.6% Disease Control Rate with a 7.7% Complete Response Rate
$タイシャ ジーン セラピーズ(TSHA.US)$ 21% FY 2023 results
$TFFファーマシューティカルズ(TFFP.US)$ 14% Clinical programs update
$ジャガーアニマルヘルス(JAGX.US)$ 14% Crofelemer commercialization
$アセリリン(SLRN.US)$ 4% Ph1/2 positive data
$デルキャス・システムズ(DCTH.US)$ 3% Closes $7M private placement
$セラス ライフサイエンシズ グループ(SLS.US)$ 0% Closes $20M offering & private placement
$イミューニック(IMUX.US)$ 1% Patent notice of allowance
$ニューリックス セラピューティクス(NRIX.US)$ 0...
Delcath Systems Receives Permanent J-Code For HEPZATO
Delcath Systems Launches Commercial Treatment Utilizing HEPZATO KIT For Treatment Of Metastatic Uveal Melanoma
•Partnered with seven clinical treatment sites to ...
まだコメントはありません